Q32 Bio Inc (QTTB)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$11.99-6.33%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · QTTB
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -77.0% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
QTTB — litigation filed
Dated 2026-07-13
Other Events. On July 13, 2026, Q32 Bio Inc. (the “Company”) used a presentation in connection with its announcement of the topline results from the Part B of the SIGNAL-AA Phase 2a signal finding clinical trial evaluating bempikibart (ADX-914) in patients with alopecia areata (“AA”), a copy of which is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K, includin…
Why it matters: Starting this program is a key step. It helps get market approval for bempikibart in severe alopecia areata.
Supportive ifThe program will start in the first half of 2027 after talks with regulators.
Worry ifThe program may be delayed or canceled. This could happen due to regulatory issues or data problems.
Why it matters: M&A could strengthen the company's position and growth prospects. Investors look for growth signals.
Supportive ifThere is news of a new acquisition or partnership that improves skills.
Worry ifNo mergers or acquisitions were reported. This shows a lack of growth plans.
Why it matters: These results will show how well bempikibart works for alopecia areata. Good data may help with more development.
Supportive ifThe reported mean percent reduction in SALT score is greater than 35.3% in the mITT population.
Worry ifThe mean percent reduction in SALT score is less than 30% in the mITT population.
Why it matters: If health care revenue growth speeds up, it could improve Q32 Bio's outlook in a maturing sector.
Supportive if3-year revenue growth in health care exceeds 12% year over year.
Worry if3-year revenue growth in health care remains below 8% year over year.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$360 on $10,000 · ±3.6% | How much price usually moves either way. |
| Bad day | $1,057 loss on $10,000 · 10.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,114 loss on $10,000 · 51.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Full results could give better insights into how well and safely bempikibart works.
Watch forPresentation of full results from Part B at a medical conference in the second half of 2026.
Also watch forNot sharing full results or negative findings could go against the first topline data.
Why it matters: Updates on cash runway are key for funding trials and operations. It affects the company's plans.
Supportive ifManagement says they have enough cash to fund operations until Phase 3 results.
Worry ifManagement warns of a possible cash shortfall or need for more funds before Phase 3 results.
Why it matters: Having enough cash is important. It helps move forward with clinical programs and keep operations running.
Supportive ifIt is confirmed that cash and cash equivalents can fund operations until late 2027.
Worry ifAnnouncement of cash shortfalls or need for additional funding before the end of 2027.
Why it matters: The 36-week results could change how effective bempikibart seems. This matters for its future in treating alopecia areata.
Supportive ifA medical conference will show positive data from the 36-week results.
Worry ifThe presentation may show poor results or safety problems. This weakens earlier findings.
Why it matters: Clear financial plans are crucial for stability. This affects investor confidence and future funding.
Supportive ifManagement shares a plan. It shows enough money to operate until Q4 2027.
Worry ifManagement does not provide a clear financial plan. This raises worries about cash.
Why it matters: Starting this program is a key step for bempikibart's path to market. It signals confidence in the drug's potential.
Supportive ifAnnouncement of the program's initiation as planned in the first half of 2027.
Worry ifDelay in starting the registration program past 1H 2027.